Inflammatory bowel disease (IBD) affects millions of adults in the U.S., causing symptoms like diarrhea, abdominal pain, and cramping. Recently, researchers in the U.K. discovered a genetic component that is present in 95% of individuals with the disorder. This genetic component, known as a “weak spot” in the DNA, boosts the activity of a gene called ETS2, which is linked to inflammatory functions that increase the risk of IBD.
Dr. Rosario Ligresti, chief of the Division of Gastroenterology at Hackensack University Medical Center, emphasized the importance of this discovery, stating that autoimmune and inflammatory diseases, including IBD, may be caused by a single gene – ETS2. The researchers found that the more this gene is activated, the higher the risk of inflammation, leading to the development of IBD.
While factors like diet and stress have been suspected to worsen IBD, the molecular switch that triggers the disease was previously unknown. This new finding opens up possibilities for developing targeted treatments to reduce the activity of the ETS2 gene and prevent the occurrence of IBD. Existing anti-inflammatory medications called MEK inhibitors are being investigated for their potential to inhibit this gene.
Although more research is needed to determine the best way to deliver these inhibitors to target cells effectively, this discovery represents a significant step towards developing more efficient therapies for inflammatory bowel disease. Patients at higher risk of developing IBD could potentially benefit from early intervention with these drugs to prevent the onset of symptoms.
James Lee, who led the research at the Crick Institute, emphasized the urgent need for better treatments for IBD, which can significantly impact the lives of those affected. By targeting specific genetic pathways involved in the disease, researchers are hopeful that more effective and safer therapies can be developed in the future.
Individuals like Lauren Golightly, who was diagnosed with Crohn’s disease in 2018, are optimistic about the potential impact of this research on improving the lives of people with IBD. The hope is that these findings will lead to innovative treatment options that could make a real difference for those living with the condition.
Overall, the discovery of the “trigger gene” in IBD represents a promising development in the field of inflammatory bowel diseases, offering new insights into the underlying causes of the condition and paving the way for personalized and effective treatments in the future.